Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with Prader Willi syndrome: a case report - Akca OF, Yilmaz S.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - August 19, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

A new method cuts the cost of drug-building chemicals
EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical industry - the amines. The amines are one of the most important classes of chemical compounds today. Amines that contain a ring-like structure - called an "aryl" group - are used widely in pharmaceuticals, such as the top-selling drugs Abilify, Crestor, Gleevec, and Lidoderm. (Source: World Pharma News)
Source: World Pharma News - August 12, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Aripiprazole reduces severity of tics in children with Tourette's disorder
(Mary Ann Liebert, Inc./Genetic Engineering News) A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group. The drug was safe, with drowsiness, nausea, and headache being the most common adverse effects, according to the study published in Journal of Child and Adolescent Psychopharmacology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2016 Category: Global & Universal Source Type: news

Aripiprazole for autism spectrum disorders (ASD)
Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011). To assess the safety and efficacy of aripiprazole as medication treatm...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news

Improving Drug Trials: Lessons Learned From AripiprazoleImproving Drug Trials: Lessons Learned From Aripiprazole
Dr Lieberman discusses the FDA's recent warning about the side effects of aripiprazole, what we can learn from this, and how we can better manage a new drug's uncertain potential in the future. Medscape Psychiatry (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 27, 2016 Category: Psychiatry Tags: Psychiatry Commentary Source Type: news

Otsuka gets in on ReCor Medical’s Paradise renal denervation device
ReCor Medical said it landed a strategic investment from Japanese conglomerate Otsuka Pharmaceutical (TYO:4578) that will bring to Asia its Paradise renal denervation device for treating hypertension. Neither side is disclosing financial terms, but the deal calls for Otsuka to receive exclusive rights to pursue clinical trials, regulatory approval and commercialization of ReCor’s Paradise device in Japan, China, Korea and elsewhere in Asia. For starters, Otsuka will test Paradise in Japan to see if it can help patients with treatment-resistant hypertension. Paradise uses ultrasound energy to ablate nerve endings ...
Source: Mass Device - May 16, 2016 Category: Medical Equipment Authors: Mark Hollmer Tags: Clinical Trials Drug-Device Combinations Funding Roundup Pharmaceuticals Otsuka Pharmaceutical ReCor Medical Source Type: news

La FDA advierte de nuevos problemas de control de impulsos en relación con el medicamento para tratar la salud mental aripiprazol (Abilify, Abilify Maintena, Aristada)
[05/03/2016] La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) advierte que se ha informado de deseos compulsivos o incontrolables de apostar, atracarse de comida, comprar y tener relaciones sexuales con el uso del fármaco antipsicótico aripiprazol (Abilify, Abilify Maintena, Aristada y sus versiones genéricas). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 9, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Warns of Impulse-control Problems With Mental Health Drug
Compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 4, 2016 Category: Pharmaceuticals Source Type: news

FDA Warns of Rare Reactions to Abilify Medication
The Food and Drug Administration warned of rare cases in which patients taking the antipsychotic medication Abilify have experienced uncontrollable urges to gamble, binge eat, shop and engage in sex. (Source: WSJ.com: Health)
Source: WSJ.com: Health - May 4, 2016 Category: Pharmaceuticals Tags: FREE Source Type: news

FDA Warns of Compulsive Behaviors Associated with Antipsychotic Aripiprazole (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The antipsychotic drug aripiprazole (marketed as Abilify, Abilify Maintena, and Aristada) is associated with compulsive or uncontrollable urges to gamble, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 3, 2016 Category: Primary Care Source Type: news

Aripiprazole linked to rare but serious compulsion problems
Rare but serious instances of impulse control problems have been reported in people taking the antipsychotic drug aripiprazole, according to a May 3 press release from the Food and Drug... (Source: Family Practice News)
Source: Family Practice News - May 3, 2016 Category: Primary Care Source Type: news

FDA Warning: Abilify Tied to Impulse Control Problems
(MedPage Today) -- In rare cases, may prompt "uncontrollable urges" (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 3, 2016 Category: Psychiatry Source Type: news

Impulse Control Problems Linked to Antipsychotic, FDA WarnsImpulse Control Problems Linked to Antipsychotic, FDA Warns
The FDA is warning of impulse control problems associated with the atypical antipsychotic aripiprazole. News Alerts (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 3, 2016 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)
[05-03-2016] The U.S. Food and Drug Administration (FDA) is warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and generics). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 3, 2016 Category: Drugs & Pharmacology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 27, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. FDA wants more from Proteus, Otsuka on ‘smart pill’ Otsuka Pharmaceutical and Proteus Digital Health said today that the FDA issued a complete response letter requesting more information from the companies for the combinat...
Source: Mass Device - April 27, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news